Eikon employs super-resolution microscopy and advanced engineering to invent novel medicines. Elkon aims to permit precise characterization of protein interactions in living cells with exceptional spatial and temporal resolution. This approach requires the integration of tools that support advanced imaging, high-performance computing, molecular and cellular biology, medicinal chemistry, and robotics, the company said.

New investors participating in the financing round include funds and accounts advised by T. Rowe Price Associates, the Canada Pension Plan Investment Board (CPP Investments), EcoR1 Capital, UC Investments, ADIA, StepStone Group, Soros Capital, Schroders Capital, Harel Insurance, General Catalyst, E15 VC, Hartford Healthcare Endowment, and AME Cloud Ventures. The financing also included participation from the company's series A investors, the Column Group, Foresite Capital, Innovation Endeavors, Lux Capital, and Horizons Ventures.

Eikon raises $148M for super-res microscopy-aided drug discovery
Eikon Therapeutics has closed $148 million in financing to integrate engineering, advanced optics, and machine learning into its super-resolution...